Zobrazeno 1 - 10
of 1 208
pro vyhledávání: ''
Publikováno v:
Reumatologia
Rheumatology, Vol 59, Iss 3, Pp 200-202 (2021)
Rheumatology, Vol 59, Iss 3, Pp 200-202 (2021)
Patient-reported outcomes (PROs) provide a means for patients to communicate with their care teams about their disease. Polymyalgia rheumatica (PMR) is considered to be one of the most common inflammatory rheumatic diseases in older adults. The Visua
Autor:
Melih Pamukcu, Tugba Izci Duran
Publikováno v:
Rheumatology international. 41(12)
Anakinra is a drug that can be administered subcutaneously as a self-injection in both children and adults. We aimed to evaluate the content, reliability, and quality of the videos most viewed on “anakinra self-injection” on YouTube, which is an
Autor:
Jette Primdahl, Maxime Dougados, Laure Gossec, Louise Falzon, Désirée van der Heijde, Iain B. McInnes, Josef S Smolen, Maarten de Wit, Andreas Kerschbaumer, Xenofon Baraliakos
Publikováno v:
Kerschbaumer, A, Smolen, J S, Dougados, M, de Wit, M, Primdahl, J, McInnes, I, van der Heijde, D, Baraliakos, X, Falzon, L & Gossec, L 2020, ' Pharmacological treatment of psoriatic arthritis : a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis ', Annals of the rheumatic diseases, vol. 79, no. 6, pp. 778-786 . https://doi.org/10.1136/annrheumdis-2020-217163
Annals of the Rheumatic Diseases, 79(6), 778-786. BMJ PUBLISHING GROUP
Annals of the Rheumatic Diseases, 79(6), 778-786. BMJ PUBLISHING GROUP
ObjectiveTo perform an update of a review of the efficacy and safety of disease-modifying antirheumatic drugs (DMARDs) in psoriatic arthritis (PsA).MethodsThis is a systematic literature research of 2015–2018 publications on all DMARDs in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7707c1e32505fac42cfd051fc1e37c0c
https://findresearcher.sdu.dk:8443/ws/files/169600720/Pharmacological_treatment_of_psoriatic_arthritis.pdf
https://findresearcher.sdu.dk:8443/ws/files/169600720/Pharmacological_treatment_of_psoriatic_arthritis.pdf
Autor:
David M. Weinreich, Alan Kivitz, George D. Yancopoulos, Joseph Gimbel, N. Skrepnik, Gregory P. Geba, Chetachi Emeremni, Paula Dakin, Neil Stahl, Stephen J. DiMartino, Haitao Gao
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesTo study the efficacy and safety of fasinumab in moderate-to-severe, chronic low back pain (CLBP).MethodsIn this phase II/III, double-blind, placebo-controlled study, patients with CLBP aged ≥35 years with inadequate pain relief/intoleran
Autor:
Janet E. Pope
Publikováno v:
Arthritis & Rheumatology. 71:659-661
Publikováno v:
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, 77(3), 336. BMJ Publishing Group
Annals of the Rheumatic Diseases, 77(3), 336. BMJ Publishing Group
ObjectivesTo assess if the Juvenile Arthritis Disease Activity Score (JADAS71) could be used to correctly identify patients with juvenile idiopathic arthritis (JIA) in need of antitumour necrosis factor therapy (anti-TNF) therapy 3 and 6 months after
Autor:
Xavier Mariette, C. Ecoffet, Christopher Cioffi, Daniel E. Furst, Clifton O. Bingham, Désirée van der Heijde, Michael E. Weinblatt, B. VanLunen, Ronald F van Vollenhoven, Paul Emery, Gerd R Burmester, Vivian P. Bykerk
Publikováno v:
Arthritis & Rheumatology (Hoboken, N.j.)
Arthritis & rheumatology (Hoboken, N.J.), 69(10), 1937-1948. John Wiley and Sons Ltd
Arthritis and Rheumatology, 69(10), 1937-1948. John Wiley and Sons Ltd
Arthritis and Rheumatology, 69(10), 1937-1948
Weinblatt, M E, Bingham, C O, Burmester, G R, Bykerk, V P, Furst, D E, Mariette, X, van der Heijde, D, van Vollenhoven, R, VanLunen, B, Ecoffet, C, Cioffi, C & Emery, P 2017, ' A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis ', Arthritis and Rheumatology, vol. 69, no. 10, pp. 1937-1948 . https://doi.org/10.1002/art.40196
Arthritis & rheumatology (Hoboken, N.J.), 69(10), 1937-1948. John Wiley and Sons Ltd
Arthritis and Rheumatology, 69(10), 1937-1948. John Wiley and Sons Ltd
Arthritis and Rheumatology, 69(10), 1937-1948
Weinblatt, M E, Bingham, C O, Burmester, G R, Bykerk, V P, Furst, D E, Mariette, X, van der Heijde, D, van Vollenhoven, R, VanLunen, B, Ecoffet, C, Cioffi, C & Emery, P 2017, ' A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis ', Arthritis and Rheumatology, vol. 69, no. 10, pp. 1937-1948 . https://doi.org/10.1002/art.40196
Objective: In disease-modifying antirheumatic drug–naive patients with early rheumatoid arthritis (RA) who had achieved sustained low disease activity (a Disease Activity Score in 28 joints using the erythrocyte sedimentation rate of ≤3.2 at both
Autor:
Pekka Lahdenne, Tadej Avcin, Stephen D. Marks, Paul A. Brogan, Bas Vastert, Yosef Uziel, Noortje Groot, Angelo Ravelli, Annet van Royen-Kerkhof, Michael W. Beresford, Seza Ozen, Sylvia Kamphuis, Pavla Dolezalova, Nienke de Graeff, Brian M. Feldman, Clarissa Pilkington, Isabelle Koné-Paut, Nico M Wulffraat, Liza J McCann, Brigitte Bader-Meunier
Publikováno v:
Annals of the Rheumatic Diseases, 76(12), 1965-1973. BMJ Publishing Group
Annals of the Rheumatic Diseases, 76(12), 1965. BMJ Publishing Group
ANNALS OF THE RHEUMATIC DISEASES
Annals of the Rheumatic Diseases, 76(12), 1965. BMJ Publishing Group
ANNALS OF THE RHEUMATIC DISEASES
Lupus nephritis (LN) occurs in 50%–60% of patients with childhood-onset systemic lupus erythematosus (cSLE), leading to significant morbidity. Timely recognition of renal involvement and appropriate treatment are essential to prevent renal damage.
Autor:
Marius Henriksen, Lars Erik Kristensen, Else Marie Bartels, Jasvinder A. Singh, Henning Bliddal, Eva Ejlersen Wæhrens, Loreto Carmona, Robin Christensen, Filip K. Knop, William J. Taylor, Henrik Gudbergsen, Fernando Perez-Ruiz, Arne Astrup, Sabrina Mai Nielsen
Publikováno v:
BASE-Bielefeld Academic Search Engine
Nielsen, S M, Bartels, E M, Henriksen, M, Wæhrens, E E, Gudbergsen, H, Bliddal, H, Astrup, A, Knop, F K, Carmona, L, Taylor, W J, Singh, J A, Perez-Ruiz, F, Kristensen, L E & Christensen, R 2017, ' Weight loss for overweight and obese individuals with gout : a systematic review of longitudinal studies ', Annals of the Rheumatic Diseases, vol. 76, no. 11, pp. 1870-1882 . https://doi.org/10.1136/annrheumdis-2017-211472
Mai Nielsen, S, Bartels, E M, Henriksen, M, Wæhrens, E E E, Gudbergsen, H, Bliddal, H, Astrup, A, Knop, F K, Carmona, L, Taylor, W J, Singh, J A, Perez-Ruiz, F, Kristensen, L E & Christensen, R 2017, ' Weight loss for overweight and obese individuals with gout : A systematic review of longitudinal studies ', Annals of the Rheumatic Diseases, vol. 76, no. 11, pp. 1870-1882 . https://doi.org/10.1136/annrheumdis-2017-211472
Annals of the Rheumatic Diseases
Nielsen, S M, Bartels, E M, Henriksen, M, Wæhrens, E E, Gudbergsen, H, Bliddal, H, Astrup, A, Knop, F K, Carmona, L, Taylor, W J, Singh, J A, Perez-Ruiz, F, Kristensen, L E & Christensen, R 2017, ' Weight loss for overweight and obese individuals with gout : a systematic review of longitudinal studies ', Annals of the Rheumatic Diseases, vol. 76, no. 11, pp. 1870-1882 . https://doi.org/10.1136/annrheumdis-2017-211472
Mai Nielsen, S, Bartels, E M, Henriksen, M, Wæhrens, E E E, Gudbergsen, H, Bliddal, H, Astrup, A, Knop, F K, Carmona, L, Taylor, W J, Singh, J A, Perez-Ruiz, F, Kristensen, L E & Christensen, R 2017, ' Weight loss for overweight and obese individuals with gout : A systematic review of longitudinal studies ', Annals of the Rheumatic Diseases, vol. 76, no. 11, pp. 1870-1882 . https://doi.org/10.1136/annrheumdis-2017-211472
Annals of the Rheumatic Diseases
ObjectivesWeight loss is commonly recommended for gout, but the magnitude of the effect has not been evaluated in a systematic review. The aim of this systematic review was to determine benefits and harms associated with weight loss in overweight and
Publikováno v:
Annals of the Rheumatic Diseases. 80:805.1-805
Background:Previous analysis of the REWARD study reported that patients with limited joint involvement have a considerable burden of disease1. Recent data suggest that patients with moderately active psoriatic arthritis (PsA) and a limited joint invo